- ►nih.gov - Free from Publisher VA Fonseca, J Rosenstock, AC Wang, KE … - Diabetes care, 2008 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A 26-week, randomized, double-blind,
placebo-controlled, parallel-group, multicenter study was carried out between
August 2004 and August 2006 to evaluate the efficacy and safety of ... Cited by 16 - Related articles - All 5 versions
RB Goldberg, VA Fonseca, KE Truitt, MR … - Archives of internal medicine, 2008 - archinte.highwire.org Methods A prospective, 16-week, multicenter, randomized, double-blind,
placebo-controlled, parallel-group study conducted at 50 sites in the United
States and 1 site in Mexico between August 12, 2004, and December 28, 2005. ... Cited by 18 - Related articles - All 5 versions
HE Bays, RB Goldberg, KE Truitt, MR Jones - Archives of internal medicine, 2008 - archinte.highwire.org Methods This 26-week, randomized, double-blind, placebo-controlled,
parallel-group study was conducted between August 2004 and July 2006 at 54 sites
in the United States and 2 in Mexico to determine the effects of ... Cited by 13 - Related articles - All 5 versions
- ►diabetesjournals.org [PDF] VA Fonseca, J Rosenstock, AC Wang, KE … - Diabetes Care, 2008 - Am Diabetes Assoc Page 1. Colesevelam Improves Glucose and Lipid Levels Colesevelam HCl Improves
Glycemic Control and Reduces LDL-Cholesterol in Patients ... Cited by 3 - Related articles - All 3 versions
NJ Parsippany - Am Diabetes Assoc 1 Corresponding author: Tulane University Health Sciences Center, 1430 Tulane
Avenue – SL 53, New Orleans, LA 70112, Email: vfonseca@tulane.edu; 2Dallas
Diabetes and Endocrine Center, Dallas, TX; 3Daiichi Sankyo Pharma ... Related articles
AB Goldfine - Current opinion in cardiology, 2008 - journals.lww.com Purpose of review: Individuals with type 2 diabetes mellitus (T2DM) have a
number of potentially modifiable risk factors, including dyslipidemia,
hypertension, and hyperglycemia, that contribute to coronary artery disease ... Cited by 5 - Related articles - All 3 versions
- ►adisonline.com B Staels, F Kuipers - Drugs, 2007 - ingentaconnect.com Bile acids promote bile formation and facilitate dietary lipid absorption.
Abstract Animal and human studies showing disturbed bile acid metabolism in
diabetes mellitus suggest a link between bile acids and glucose control. ... Cited by 30 - Related articles - BL Direct - All 8 versions
MH Davidson - Expert Opin. Pharmacother., 2007 - informahealthcare.com Bile-acid sequestrants augment cholesterol excretion via enhanced conversion to
bile acids, and act to lower low-density lipoprotein cholesterol (LDL-C),
especially when combined with other cholesterol-lowering drugs. Colesevelam ... Cited by 12 - Related articles - BL Direct - All 7 versions
M Florentin, EN Liberopoulos, DP Mikhailidis, … - Current Medical Research and Opinion®, 2008 - informahealthcare.com Objective: Hypercholesterolaemia is a major risk factor for atherosclerosis and
coronary heart disease. Treatment with lipid lowering agents reduces the risk of
vascular events. Colesevelam is a novel bile acid sequestrant (BAS) ... Cited by 13 - Related articles - All 6 versions
K Tziomalos, VG Athyros, DP Mikhailidis - Nature Clinical Practice Endocrinology & Metabolism, 2008 - nature.com VG Athyros is Assistant Professor in Internal Medicine and Academic Head of
Atherosclerosis and Metabolic Syndrome Out-patient Clinics, Second Propedeutic
Department of Internal Medicine, Aristotle University, Hippokration ... Cited by 3 - Related articles - All 4 versions
